Terbinafine Hcl

Verify with FDA CVM →

58 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
58
Total Reports
6
Deaths Reported
1030.0%
Death Rate

Active Ingredients

Terbinafine Hcl

Administration Routes

UnknownOral

Species Affected

Dog 53
Cat 5

Most Affected Breeds

Shih Tzu 7
Retriever - Labrador 4
Chihuahua 4
Domestic Shorthair 4
Terrier - Yorkshire 3
Dachshund (unspecified) 3
Terrier - Bull - American Pit 3
Crossbred Canine/dog 2
Terrier - West Highland White 2
Spaniel - Cocker American 2

Most Reported Reactions

Vomiting 11
Lethargy (see also Central nervous system depression in 'Neurological') 10
Diarrhoea 8
Seizure NOS 6
Lack of efficacy - NOS 5
Fungal skin infection NOS 5
Pruritus 5
Other abnormal test result NOS 4
Otitis NOS 4
PR-SKIN, LESION(S) 4
Skin lesion NOS 4
Elevated serum alkaline phosphatase (SAP) 4

Outcome Breakdown

Ongoing
39 (67.2%)
Recovered/Normal
10 (17.2%)
Died
3 (5.2%)
Euthanized
3 (5.2%)
Outcome Unknown
3 (5.2%)

Data Summary

Metric Value
Total adverse event reports 58
Reports involving death 6
Case-fatality rate (reported events) 1030.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Terbinafine Hcl Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 58 adverse event reports referencing Terbinafine Hcl, including 6 reports in which the animal died — a 1030.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Terbinafine Hcl. Reported administration routes include Unknown, Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Terbinafine Hcl reports are Dog (53 reports), Cat (5 reports), with Dog accounting for the largest share. Within those species, Shih Tzu (7), Retriever - Labrador (4), Chihuahua (4) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Terbinafine Hcl are Vomiting (11), Lethargy (see also Central nervous system depression in 'Neurological') (10), Diarrhoea (8), Seizure NOS (6). Of the 58 reports with a coded outcome, Ongoing is the leading category at 67.2%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Terbinafine Hcl.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial